Skip to Main Content

Author Details

Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
2003
193
56
Jake Y. Chen (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36672327BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer.Cancers (Basel)2023
37639774H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase.Drug Resist Updat2023
36923821Editorial: AI and data science in drug development and public health: Highlights from the MCBIOS 2022 conference.Front Big Data2023
36672327BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer.Cancers (Basel)2023
37639774H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase.Drug Resist Updat2023
36923821Editorial: AI and data science in drug development and public health: Highlights from the MCBIOS 2022 conference.Front Big Data2023
35105868οNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer.Nat Commun2022
35205126DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets.Biology (Basel)2022
35105868οNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer.Nat Commun2022
35205126DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets.Biology (Basel)2022
33097494Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers.Clin Cancer Res2021
33795352Novel Human-Derived <i>RET</i> Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling.Mol Pharmacol2021
34001994A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.NPJ Precis Oncol2021
33462489Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations.Nat Ecol Evol2021
33649199Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.Proc Natl Acad Sci U S A2021
33378592Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.Mol Carcinog2021
33155727MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.J Leukoc Biol2021
33097494Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers.Clin Cancer Res2021
33087417Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft.Mol Cancer Res2021
33084222Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer.Mol Oncol2021
34520464Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.PLoS Comput Biol2021
33795352Novel Human-Derived <i>RET</i> Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling.Mol Pharmacol2021
33649199Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.Proc Natl Acad Sci U S A2021
34520464Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.PLoS Comput Biol2021
34001994A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.NPJ Precis Oncol2021
33378592Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.Mol Carcinog2021
33462489Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations.Nat Ecol Evol2021
33087417Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft.Mol Cancer Res2021
33084222Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer.Mol Oncol2021
33155727MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.J Leukoc Biol2021
32533049Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels.Commun Biol2020
31911553Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma.Cancer Res2020
32414750Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.Clin Cancer Res2020
32409712Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.Nat Commun2020
32154490Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report.J Endocr Soc2020
32092353Translational genomics for rare cancers: Challenges and opportunity.Semin Cancer Biol2020
31655118The mutational landscape of mucosal melanoma.Semin Cancer Biol2020
32990596Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.Elife2020
32708981Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.Cancers (Basel)2020
32599072Role of mTOR As an Essential Kinase in SCLC.J Thorac Oncol2020
32533049Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels.Commun Biol2020
32513939MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.Cell Death Dis2020
32562448Loss of prdm1a accelerates melanoma onset and progression.Mol Carcinog2020
32499299First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.Mol Cancer Ther2020
31655118The mutational landscape of mucosal melanoma.Semin Cancer Biol2020
31911553Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma.Cancer Res2020
32092353Translational genomics for rare cancers: Challenges and opportunity.Semin Cancer Biol2020
32708981Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.Cancers (Basel)2020
32599072Role of mTOR As an Essential Kinase in SCLC.J Thorac Oncol2020
32990596Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.Elife2020
  • 1 - 50 of 386

Recommended Authors

Raunak Shrestha
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 0
Wail Ba-Alawi
Princess Margaret Cancer Centre, University Health Network, University Ave.
Career Start Year 2013
Number of shared co-authors 2
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 2
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 1
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 3
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 3
Dennis Wang
Sheffield Institute of Translational Neuroscience, University of Sheffield
Career Start Year 2006
Number of shared co-authors 4
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 3
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 4
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 7
Gabriela Alexe
Dana-Farber Cancer Institute
Career Start Year 2004
Number of shared co-authors 8
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 7
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 4
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Jonathan R Dry
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 5
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 3
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 2
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 4
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 1
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 8
Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Career Start Year 1999
Number of shared co-authors 8
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 9
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 6
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 4
Pablo Tamayo
University of California San Diego
Career Start Year 1988
Number of shared co-authors 7

Collaborators

Wells A Messersmith
University of Colorado Anschutz Medical Campus
Co-authored papers 29
Antonio Jimeno
University of Colorado School of Medicine
Co-authored papers 22
Jaewoo Kang
Korea University
Co-authored papers 17
William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Co-authored papers 13
Minjae Yoo
University of Colorado Anschutz Medical Campus
Co-authored papers 13
Dexiang Gao
University of Colorado Anschutz Medical Campus
Co-authored papers 13
James DeGregori
University of Colorado Anschutz Medical Campus
Co-authored papers 12
Stephen B Keysar
University of Colorado Denver
Co-authored papers 11
Minji Jeon
Korea University College of Medicine
Co-authored papers 8
Jimin Shin
Sungkyunkwan University School of Medicine
Co-authored papers 7
Katherine R Singleton
Duke University
Co-authored papers 7
Vadym Zaberezhnyy
University of Colorado Anschutz Medical Campus
Co-authored papers 6
Sunkyu Kim
Korea University
Co-authored papers 5
Raimond L Winslow
Johns Hopkins University
Co-authored papers 5
Rene Gonzalez
University of Colorado Anschutz Medical Campus
Co-authored papers 5
Christopher C Porter
Emory University School of Medicine
Co-authored papers 4
Anirban Maitra
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Martin D McCarter
University of Colorado School of Medicine
Co-authored papers 4
Steven E Robinson
University of Colorado Anschutz Medical Campus
Co-authored papers 4
Veronica Clavijo Jordan
Harvard Medical School
Co-authored papers 3
Angelo D'Alessandro
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Co-authored papers 3
Donghyeon Park
Korea University
Co-authored papers 3
Donald Geman
Johns Hopkins University
Co-authored papers 3
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 3
Andrii I Rozhok
University of Colorado Anschutz Medical Campus
Co-authored papers 3
Gregory N Gan
Co-authored papers 2
Joshua Chuck Harrell
Virginia Commonwealth University
Co-authored papers 2
James C Costello
University of Colorado Anschutz Medical Campus
Co-authored papers 2
Biniam Adane
The Broad Institute of MIT and Harvard
Co-authored papers 2
Release 1.2